CureMatch will analyze molecular profiles of US Special Operations Forces cancer patients and produce reports with treatment strategies.
NEW YORK – Radiopharm Theranostics on Tuesday said it was cleared by Australian regulators to begin a Phase I trial of its KLK3-targeting radiotherapeutic, RAD 402, for the treatment of metastatic or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback